课题基金 / 基金详情

ER stress pathways regulate T-cell allogeneic and anti-tumor responses

ER stress pathways regulate T-cell allogeneic and anti-tumor responses
ER应激通路调节T细胞同种异体和抗肿瘤反应
批准号:
10577856
负责人:
Xue-Zhong Yu
金额:
$17.87万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-01 至 2024-02-29

项目摘要

项目成果

Xue-Zhong Yu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Summary Unfolded protein response (UPR) is a highly conserved pathway that allows the cell to manage endoplasmic reticulum (ER) stress in response to protein misfolding. Three master regulators control the UPR: IRE1α, PERK, and ATF6. The primary goal of UPR is to induce transcriptional and translational programs to maintain ER homeostasis for cell survival. Thus, dysfunctional UPR signaling has been shown to contribute to various health conditions including metabolic diseases, degenerative diseases, inflammatory disorders, and cancer. The ER stress pathways have been studied in cancer cells extensively, but have been overall understudied in T-cell immunity and tolerance. There are several knowledge gaps in understanding the impacts of the ER stress pathways in T-cell immunity against cancer. Our long-term goal is to develop novel strategies through targeting the ER stress pathways for improving cancer immunotherapy of human malignancies. the overall objectives of this application are to provide critical information towards more understanding the impacts of ER stress pathways on immune responses against cancer, which will eventually help to fulfill our long-term goal. Our central hypothesis is that the IRE-1α/XBP-1 and PERK/CHOP pathways differentially regulate CD4 and CD8 anti-tumor responses in microenvironment dependent manner. The hypothesis has been formulated based on preliminary data generated from in vitro and in vivo experiments using genetically modified mice with T-cell conditional knock-out (KO) for XBP-1, PERK or both. This hypothesis will be tested in the following two Specific Aims: 1) To define the role of XBP-1 and PERK in T-cell mediated graft-versus-host (GVH) and graft- versus-leukemia (GVL) responses; 2) To define the impact of XBP-1 and PERK in T-cell immunity against tumor. The proposed study is expected to provide a strong guidance for improving T-cell based cancer immunotherapy by targeting the ER stress pathways and to provide a solid foundation for further studying underlying mechanisms of ER stress pathways in regulating T-cell immunity.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
  • 批准号:
    10364948
  • 项目类别:
  • 资助金额:
    $55.29万
  • 财政年份:
    2022
  • 负责人:
    Xue-Zhong Yu
  • 依托单位:
Targeting PIM-2 Kinase for Improving Cancer Immunotherapy
  • 批准号:
    10559633
  • 项目类别:
  • 资助金额:
    $52.8万
  • 财政年份:
    2022
  • 负责人:
    Xue-Zhong Yu
  • 依托单位:
ER stress pathways regulate T-cell allogeneic and anti-tumor responses
  • 批准号:
    10430505
  • 项目类别:
  • 资助金额:
    $21.88万
  • 财政年份:
    2022
  • 负责人:
    Xue-Zhong Yu
  • 依托单位:
Control of GVHD by Probiotics with individual Commensal Bacteria
  • 批准号:
    10434993
  • 项目类别:
  • 资助金额:
    $62.39万
  • 财政年份:
    2022
  • 负责人:
    Xue-Zhong Yu
  • 依托单位:
海外基金